Disclosed is a transdermal absorptive liquid preparation in which a medicament or a salt thereof is colloidally dispersed in propylene glycol or a propylene glycol-containing solvent, whose transdermal permeability of the medicament is excellent, problem of skin irritation is reduced. This transdermal absorptive liquid formulation has a mode of particle diameter at around 100 nm, and an average particle size of 50 to 500 nm. This transdermal absorptive liquid formulation makes marked improvement in the transdermal permeability by further containing an absorption promoter such as triethanolamine.

Polymers, including homopolymers, copolymers, block copolymers, comprising poly(pentadecyl caprolactone), methods of making the polymers, and pressure sensitive adhesives including the polymers.

The present invention relates to a dosage form for transdermal administration of at least one active pharmaceutical ingredient with a logP≥3, comprising at least one penetration accelerator, wherein the at least one penetration accelerator comprises dimethylethylene urea, the use of such a dosage form as a medicament, and the use of dimethylethylene urea as penetration accelerator to increase the skin penetration of active pharmaceutical ingredients with a logP≥3.

A patch includes: a support; and an adhesive layer on the support. The adhesive layer includes blonanserin or a salt thereof, a thermoplastic elastomer, and a higher fatty acid ester.

A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.

Various embodiments of a drug delivery device and a method of using such device are disclosed. The drug delivery device includes a backing layer having a first major surface and a second major surface, and an array of patch segments defined by segment separation lines disposed in the backing layer. Each segment separation line is adapted to enhance separation of one or more patch segments from the array of patch segments. Further, a patch segment of the array of patch segments includes a polygonal shape.

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

A crosslinkable composition is useful for preparing a skin contact adhesive or a coating on a substrate. The crosslinkable composition includes (A) a polyurethane-polyorganosiloxane copolymer and (B) a curing catalyst. The skin contact adhesive prepared by crosslinking the crosslinkable composition is useful in applications such as adhesives for medical tapes, adhesives for wound dressings, adhesives for prosthetics, ostomy appliance adhesives, adhesives for medical monitoring appliances, adhesives for scar therapy treatments, adhesives for cosmetic patches, and transdermal drug delivery systems.

There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.